Phase III aims to complete the information needed to support what?

• A. Determine manufacturing scale-up
• B. Evaluate pharmacodynamics
• C. Identify adverse event rates
• D. Complete the information needed to support instructions for use of the drug

Answer: (D)

Phase III is about gathering enough information to support how the drug should be used, including the labeling and instructions for use. In this phase, data are collected in larger, more diverse patient groups to confirm efficacy and monitor safety, and crucially to define the details that appear on the product label—indications, dosing, routes of administration, preparation and storage, contraindications, warnings, and other usage instructions. This labeling information helps clinicians know exactly how to prescribe and administer the drug safely and effectively.

Other elements like manufacturing scale-up are addressed earlier in development and transfer to manufacturing, pharmacodynamics data are typically established earlier in the program, and safety data (adverse event rates) are gathered throughout but are most valuable when compiled to support the final labeling and use instructions.